CYP3A4 and heart disorder: On the other hand, this finding suggests that further studies should be considered to evaluate the safety of domperidone administration in patients affected by heart diseases, electrolytic disorders, or those under treatment with drugs directly responsible for a QT interval increase or that have strong cytochrome P450 3A4 (CYP3A4) inhibitory activity [12,17,18,19].